img Leseprobe Leseprobe

Current Applications for Overcoming Resistance to Targeted Therapies

Manpreet Sambi (Hrsg.), Bessi Qorri (Hrsg.), Myron R. Szewczuk (Hrsg.)

PDF
ca. 96,29
Amazon iTunes Thalia.de Weltbild.de Hugendubel Bücher.de ebook.de kobo Osiander Google Books Barnes&Noble bol.com Legimi yourbook.shop Kulturkaufhaus ebooks-center.de
* Affiliatelinks/Werbelinks
Hinweis: Affiliatelinks/Werbelinks
Links auf reinlesen.de sind sogenannte Affiliate-Links. Wenn du auf so einen Affiliate-Link klickst und über diesen Link einkaufst, bekommt reinlesen.de von dem betreffenden Online-Shop oder Anbieter eine Provision. Für dich verändert sich der Preis nicht.

Springer International Publishing img Link Publisher

Naturwissenschaften, Medizin, Informatik, Technik / Nichtklinische Fächer

Beschreibung

Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.

Weitere Titel in dieser Kategorie
Cover Prostate Cancer
Jovan Hadzi-Djokic
Cover Cancer Stem Cells
Gianpaolo Papaccio
Cover Kinesis
Mac Erlaine Donal Mac Erlaine

Kundenbewertungen

Schlagwörter

breast cancer, colorectal cancer, prostate cancer, pancreatic cancer, chemoresistance, drug development, pathophysiology of aggressive cancers